305 related articles for article (PubMed ID: 28972818)
21. Expression of gamma-subunit of enolase, neuron-specific enolase, in human non-neuroendocrine tumors and derived cell lines.
Påhlman S; Esscher T; Nilsson K
Lab Invest; 1986 May; 54(5):554-60. PubMed ID: 3009968
[TBL] [Abstract][Full Text] [Related]
22. Microtubule-associated protein-2: a new sensitive and specific marker for pulmonary carcinoid tumor and small cell carcinoma.
Liu Y; Sturgis CD; Grzybicki DM; Jasnosz KM; Olson PR; Tong M; Dabbs DD; Raab SS; Silverman JF
Mod Pathol; 2001 Sep; 14(9):880-5. PubMed ID: 11557784
[TBL] [Abstract][Full Text] [Related]
23. Neuroendocrine marker expression in cervical carcinomas of non-small cell type.
Chavez-Blanco A; Taja-Chayeb L; Cetina L; Chanona-Vilchis G; Trejo-Becerril C; Perez-Cardenas E; Segura-Pacheco B; Acuña-González C; Dueñas-Gonzalez A
Int J Gynecol Pathol; 2002 Oct; 21(4):368-74. PubMed ID: 12352185
[TBL] [Abstract][Full Text] [Related]
24. Chromogranin-A as a serum marker for neuroendocrine tumors: comparison with neuron-specific enolase and correlation with immunohistochemical findings.
Giovanella L; La Rosa S; Ceriani L; Uccella S; Erba P; Garancini S
Int J Biol Markers; 1999; 14(3):160-6. PubMed ID: 10569138
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical localization of neuron-specific enolase in gastroenteropancreatic neuroendocrine tumors. Correlation with tissue and serum levels of neuron-specific enolase.
Simpson S; Vinik AI; Marangos PJ; Lloyd RV
Cancer; 1984 Oct; 54(7):1364-9. PubMed ID: 6088026
[TBL] [Abstract][Full Text] [Related]
26. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects.
Isgrò MA; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():125-43. PubMed ID: 26530364
[TBL] [Abstract][Full Text] [Related]
27. Correlation between chromogranin A, neuron-specific enolase and synaptophysin expression, and some clinico-pathological features of colorectal cancer.
Famulski W; Sulkowska M; Miller-Famulska D; Kisielewski W; Sulkowski S
Folia Histochem Cytobiol; 2001; 39(2):155-6. PubMed ID: 11374802
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Clinicopathological Features and Prognostic Factors in 39 Cases of Bladder Neuroendocrine Carcinoma.
Zhou HH; Liu LY; Yu GH; Qu GM; Gong PY; Yu X; Yang P
Anticancer Res; 2017 Aug; 37(8):4529-4537. PubMed ID: 28739749
[TBL] [Abstract][Full Text] [Related]
29. Clinical biochemistry of neuron specific enolase.
Kaiser E; Kuzmits R; Pregant P; Burghuber O; Worofka W
Clin Chim Acta; 1989 Jul; 183(1):13-31. PubMed ID: 2548772
[TBL] [Abstract][Full Text] [Related]
30. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
Georgantzi K; Sköldenberg EG; Stridsberg M; Kogner P; Jakobson Å; Janson ET; Christofferson RHB
Pediatr Hematol Oncol; 2018 Mar; 35(2):156-165. PubMed ID: 29737901
[TBL] [Abstract][Full Text] [Related]
31. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
32. [A neuron-specific enolase (NSE) positive leiomyosarcoma].
Ueno H; Asami M; Yoneda R; Ogura M; Muraoka A; Oribe T; Suzuki K; Maeda M; Chinzei T; Yamashiro K
Gan No Rinsho; 1990 Dec; 36(15):2616-22. PubMed ID: 2266593
[TBL] [Abstract][Full Text] [Related]
33. Re: Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Dittadi R; Gion M
Clin Biochem; 2013 Aug; 46(12):1145. PubMed ID: 23608355
[No Abstract] [Full Text] [Related]
34. Expression of erythropoietin and neuroendocrine markers in clear cell renal cell carcinoma.
Mjønes PG; Nordrum IS; Qvigstad G; Sørdal Ø; Rian LL; Waldum HL
APMIS; 2017 Mar; 125(3):213-222. PubMed ID: 28233444
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
36. A monoclonal antibody against neuron-specific enolase. Immunohistochemical comparison with a polyclonal antiserum.
Thomas P; Battifora H; Manderino GL; Patrick J
Am J Clin Pathol; 1987 Aug; 88(2):146-52. PubMed ID: 3618548
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India.
Rekhi B; Patil B; Deodhar KK; Maheshwari A; A Kerkar R; Gupta S; Tongaonkar HB; Shrivastava SK
Ann Diagn Pathol; 2013 Feb; 17(1):1-9. PubMed ID: 22534245
[TBL] [Abstract][Full Text] [Related]
38. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Braga F; Ferraro S; Mozzi R; Dolci A; Panteghini M
Clin Biochem; 2013 Jan; 46(1-2):148-51. PubMed ID: 23000312
[TBL] [Abstract][Full Text] [Related]
39. Frequent expression of neuroendocrine markers in mucinous tubular and spindle cell carcinoma of the kidney.
Kuroda N; Hes O; Miyazaki E; Shuin T; Enzan H
Histol Histopathol; 2006 Jan; 21(1):7-10. PubMed ID: 16267782
[TBL] [Abstract][Full Text] [Related]
40. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]